Alprazolam in clinical practice Review article
Article Sidebar
Main Article Content
Abstract
Alprazolam is a potent benzodiazepine, commonly used for the treatment of anxiety disorders, especially panic disorder, but also in the treatment of generalized anxiety disorder (GAD), and social anxiety disorder. It also possesses antidepressant properties. Alprazolam is available for oral administration as imminent-release tablets and extended-release tablets. Withdrawal symptoms or rebound symptoms may occur after ceasing treatment abruptly. Because of gradually increasing tolerance, alprazolam should be administered not longer than 12 weeks. Alprazolam is very effective and well-tolerated, when administered strictly according to medical standards.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A Review of Alprazolam Use, Misuse, and Withdrawal. J Addict Med 2018; 12(1): 4-10.
3. Gladsjo JA, Rapaport MH, McKinney R et al. Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder. J Clin Psychopharmacol 2001; 21(2): 131-138.
4. Dawson GW, Jue SG, Brogden RN. Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs 1984; 27(2): 132-147.
5. Evans RL. Alprazolam. Drug Intell Clin Pharm 1981; 15(9): 633-638.
6. Singh T, Rajput MI. Psychiatry (Edgmont) 2005; 2(11): 32.
7. Greiss KC, Fogari R. Double-blind clinical assessment of alprazolam, a new benzodiazepine derivative, in the treatment of moderate to severe anxiety. J Clin Pharmacol 1980; 20(11-12): 693-699.
8. Seeley WW, Turetsky N, Reus VI, Wolkowitz OM. Benzodiazepines in schizophrenia: prefrontal cortex atrophy predicts clinical response to alprazolam augmentation. World J Biol Psychiatry 2002; 3(4): 221-224.
9. Cohn JB, Wilcox CS. Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder. Pharmacotherapy 1984; 4(2): 93-98.
10. Marks IM, Swinson RP, Başoğlu M et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 1993; 162: 776-787.
11. Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol 1998; 18(6 Supl 2): 12S-18S.
12. Huybrechts I. The pharmacology of alprazolam: a review. Clin Ther 1991; 13(1): 100-117.
13. Dueñas-Laita A, Ruiz-Muñoz P, Armentia A et al. Successful treatment of chronic drug-resistant urticaria with alprazolam. J Allergy Clin Immunol 2009; 123(2): 504-505.
14. Taylor CB, Hayward C, King R et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebocontrolled trial. J Clin Psychopharmacol 1990; 10(2): 112-118.
15. Moylan S, Staples J, Ward SA et al. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. J Clin Psychopharmacol 2011; 31(5): 647-652.
16. Dickinson B, Rush PA, Radcliffe AB. Alprazolam use and dependence. A retrospective analysis of 30 cases of withdrawal. West J Med 1990; 152(5): 604-608.
17. Chowdhury ZS, Morshed MM, Shahriar M et al. The Effect of Chronic Alprazolam Intake on Memory, Attention, and Psychomotor Performance in Healthy Human Male Volunteers. Behav Neurol 2016; 2016: 3730940. https://doi.org/10.1155/2016/3730940.
18. Kiliç C, Curran HV, Noshirvani H et al. Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients. Psychol Med 1999; 29(1): 225-231.
19. Hegel MT, Ravaris CL, Ahles TA. Combined cognitive-behavioral and time-limited alprazolam treatment of panic disorder. Behavior Therapy 1994; 25(2): 183-195.